Hormone-refractory prostate cancer: An evolving standard of care

被引：0

|

作者：

Small, EJ

Reese, DM

Vogelzang, NJ

机构：

[1] Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94115 USA

[2] Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA

来源：

SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：61 / 67

页数：7

相关论文

共 50 条

[31] Hormone-refractory prostate cancer responding to capecitabine
El-Rayes, BF
Black, CA
Ensley, JF
UROLOGY, 2003, 61 (02)
[32] Docetaxel and exisulind in hormone-refractory prostate cancer
Ryan, CW
Stadler, WM
Vogelzang, NJ
SEMINARS IN ONCOLOGY, 2001, 28 (04) : 56 - 61
[33] Future therapies in hormone-refractory prostate cancer
Smith, MR
Nelson, JB
UROLOGY, 2005, 65 (5A) : 9 - 16
[34] Hormone-refractory prostate cancer responding to bevacizumab
Iacobelli, Stefano
INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (08) : 754 - 754
[35] Chemotherapy for the treatment of hormone-refractory prostate cancer
Petrylak, DP
EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) : 15 - 23
[36] The continuing challenge of hormone-refractory prostate cancer
Sartor, Oliver
CLINICAL GENITOURINARY CANCER, 2006, 4 (04) : 238 - 239
[37] The role of bisphosphonates in hormone-refractory prostate cancer
Saad, F
Karakiewicz, P
Perrotte, P
WORLD JOURNAL OF UROLOGY, 2005, 23 (01) : 14 - 18
[38] Docetaxel for hormone-refractory prostate cancer Reply
Damber, Jan-Erik
Aus, Gunnar
LANCET, 2008, 372 (9648): : 1461 - 1462
[39] Docetaxel in hormone-refractory metastatic prostate cancer
Oh, WK
DRUGS, 2005, 65 (16) : 2296 - 2297
[40] Neuroendocrine differentiation and hormone-refractory prostate cancer
Abrahamsson, PA
PROSTATE, 1996, : 3 - 8

← 1 2 3 4 5 →